This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fenderson, R. W. Articles by Samuel, P. Search for Related Content PubMed PubMed Citation Articles by Fenderson, R. W. Articles by Samuel, P. Social Bookmarking                         What's this?

Effect of Gemfibrozil on Serum Lipids in Man

Arteriosclerosis Research Laboratory, Long Island Jewish-Hillside Medical Center, New Hyde Park, NY, Manhasset Medical Center Division, Manhasset, NY

Stanley Deutsch

Arteriosclerosis Research Laboratory, Long Island Jewish-Hillside Medical Center, New Hyde Park, NY, Manhasset Medical Center Division, Manhasset, NY

Eli Menachemi

Arteriosclerosis Research Laboratory, Long Island Jewish-Hillside Medical Center, New Hyde Park, NY, Manhasset Medical Center Division, Manhasset, NY

Bruce Chin

Arteriosclerosis Research Laboratory, Long Island Jewish-Hillside Medical Center, New Hyde Park, NY, Manhasset Medical Center Division, Manhasset, NY

Paul Samuel

Arteriosclerosis Research Laboratory, Long Island Jewish-Hillside Medical Center, New Hyde Park, NY, Manhasset Medical Center Division, Manhasset, NY

The effect of gemfibrozil, a new lipid-lowering agent, was studied in 22 patients. Each patient served as his own control in a double blind study. The administration of gemfibrozil, for a period of 24 months, 1200 mg daily, reduced mean serum triglyceride levels by 45.6% (p<0.001) and mean serum cholesterol levels by 8.3% (p<0.001). Mean serum HDL cholesterol was increased by 32.3% (p<.0001) and mean serum LDL cholesterol levels were decreased by 11.4% (p<0.01). Mean serum VLDL cholesterol was decreased by 45.9% (p<0.001). A 3-hour glucose-tolerance test was done in each patient during a placebo-control period and during the administration of gemfibrozil. Mean plasma glucose was moderately increased during the administration of gemfibrozil at all points on the glucose tolerance curve, and to levels of significance at one (p<0.05) and two hours (p<0.02). There was no effect of the drug on serum immunoreactive insulin. No subjective side effects were apparent.

Angiology, Vol. 33, No. 9, 581-593 (1982)
DOI: 10.1177/000331978203300904


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?